dc.creator | Losa, F. | es |
dc.creator | Iglesias, L. | es |
dc.creator | Pane, M. | es |
dc.creator | Sanz, J. | es |
dc.creator | Nieto, B. | es |
dc.creator | Fuste, V. | es |
dc.creator | Cruz Merino, Luis de la | es |
dc.creator | Concha, A. | es |
dc.creator | Balana, C. | es |
dc.creator | Matias-Guiu, X. | es |
dc.date.accessioned | 2024-03-11T15:23:51Z | |
dc.date.available | 2024-03-11T15:23:51Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Losa, F., Iglesias, L., Pane, M., Sanz, J., Nieto, B., Fuste, V.,...,Matias-Guiu, X. (2018). 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary. Clinical and Translational Oncology, 20 (11), 1361-1372. https://doi.org/10.1007/s12094-018-1899-z. | |
dc.identifier.issn | 1699-048X | es |
dc.identifier.issn | 1699-3055 | es |
dc.identifier.uri | https://hdl.handle.net/11441/156107 | |
dc.description.abstract | Cancer of unknown primary (CUP) is defned as a heterogeneous group of tumours that present with metastasis, and in which
attempts to identify the original site have failed. They difer from other primary tumours in their biological features and how
they spread, which means that they can be considered a separate entity. There are several hypotheses regarding their origin,
but the most plausible explanation for their aggressiveness and chemoresistance seems to involve chromosomal instability.
Depending on the type of study done, CUP can account for 2–9% of all cancer patients, mostly 60–75 years old. This article
reviews the main clinical, pathological, and molecular studies conducted to analyse and determine the origin of CUP.The
main strategies for patient management and treatment, by both clinicians and pathologists, are also addressed. | es |
dc.format | application/pdf | es |
dc.format.extent | 12 p. | es |
dc.language.iso | eng | es |
dc.publisher | Springer | es |
dc.relation.ispartof | Clinical and Translational Oncology, 20 (11), 1361-1372. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Cancer of unknown primary | es |
dc.subject | Diagnosis | es |
dc.subject | Immunohistochemistry | es |
dc.subject | Biopsy | es |
dc.subject | Prognosis | es |
dc.subject | Chemotherapy | es |
dc.subject | Molecular pathology | es |
dc.subject | Histopathology | es |
dc.title | 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://link.springer.com/article/10.1007/s12094-018-1899-z | es |
dc.identifier.doi | 10.1007/s12094-018-1899-z | es |
dc.contributor.group | Universidad de Sevilla. CTS151: Bioquímica médica. | es |
dc.journaltitle | Clinical and Translational Oncology | es |
dc.publication.volumen | 20 | es |
dc.publication.issue | 11 | es |
dc.publication.initialPage | 1361 | es |
dc.publication.endPage | 1372 | es |